Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis

Immune checkpoint inhibitors (ICIs) present clinicians with the challenge of managing immune-related adverse events (irAEs), which can range from mild to severe due to immune system activation 1. While guidelines recommend discontinuing ICIs for grade 3 partial and all grade 4 irAEs, there is growin...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Céline Eldani, Marie Kostine, Maxime Faure, Estibaliz Lazaro, Claire Rigothier, Jean Baptiste Hiriart, Bérénice Teulières, Florian Poullenot, Magalie Haissaguerre, Maeva Zysman, Rémi Veillon, Charlotte Vergnenegre, Nahema Issa, Charlotte Domblides, Sorilla Mary-Prey, Marie Beylot-Barry, Anne Pham-Ledard, Caroline Dutriaux, Guilhem Sole, Fanny Duval, Emilie Gerard
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Frontiers Media S.A. 2024-07-01
سلاسل:	Frontiers in Oncology
الموضوعات:	immune checkpoint inhibitors (ICIs) immune related adverse events (irAEs) rechallenge neurological immune-related adverse events myocarditis
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1403658/full
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!